Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
Journal article published in 2019 by
Matthew Lunning,
Julie Vose 
,
Loretta Nastoupil,
Nathan Fowler,
Jan A. Burger ,
William G. Wierda,
Marshall T. Schreeder,
Tanya Siddiqi,
Christopher R. Flowers,
Jonathon B. Cohen,
Peter Sportelli,
Hari P. Miskin,
Michael S. Weiss,
Susan O’Brien
,
Loretta Nastoupil,
Nathan Fowler,
Jan A. Burger ,
William G. Wierda,
Marshall T. Schreeder,
Tanya Siddiqi,
Christopher R. Flowers,
Jonathon B. Cohen,
Peter Sportelli,
Hari P. Miskin,
Michael S. Weiss,
Susan O’Brien
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points U2 exhibited low rates of immune-mediated toxicities associated with other PI3K-δ, including diarrhea, colitis, pneumonia, and hepatic toxicity. This combination had promising preliminary activity across a broad range of B-cell malignancies, including a 17% complete response rate.